FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2010
Commission File Number: 000-33295
3SBIO INC.
(Translation of registrant’s name into English)
No. 3 A1, Road 10
Shenyang Economy & Technology Development Zone
Shenyang 110027
People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A
3SBio Inc. is furnishing under the cover of Form 6-K:
Exhibit 99.1 Press release, dated August 24, 2010, regarding that 3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
By: | /s/ Dr. Jing Lou | |
Name: | Dr. Jing Lou | |
Title: | Chief Executive Officer |
Date: September 7, 2010
EXHIBIT INDEX
Exhibit No. | Description | |
Exhibit 99.1 | Press release, dated August 24, 2010, regarding that 3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China. |